A total of 105 pregnancies were included, with 46 exposed to mifepristone alone, and 59 exposed to both mifepristone and misoprostol. There were 94 live births (90.4%) and 10 (9.6%) miscarriages (including one with major malformation). Elective termination of pregnancy was performed after the subsequent diagnosis of trisomy 21 in one case. The overall rate of major congenital malformations was 4.2% (95% CI 1.2-10.4%), with two cases among 38 patients exposed to mifepristone alone, and two cases among 57 patients exposed to both mifepristone and misoprostol.
This first prospective study found that the rate of major malformations after first-trimester exposure to mifepristone is only slightly higher than the expected 2-3% rate in the general population. Such findings provide reassuring data for risk evaluation for continuation of pregnancy after mifepristone exposure.
Source Citation (MLA 7th Edition)
"Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study." BJOG: An International Journal of Obstetrics and Gynaecology 120.5 (2013): 568+. Academic OneFile. Web. 20 Apr. 2013.
Gale Document Number: GALE|A322061984